Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non-alcoholic steatohepatitis (NASH).

Ceramide is a central molecule of sphingolipid metabolism and is involved in the development of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). It has already been reported that the inhibition of serine palmitoyltransferase (SPT), the rate-limiting enzyme in the sphingolipid biosynthetic pathway, has an inhibitory effect on hepatic lipidosis, but its effect on severe hepatic fibrosis is not clear. In this study, we examined whether a SPT inhibitor could suppress the activation of hepatic stellate cells (HSC) and ameliorate the progression of NASH. Effects on sphingolipid metabolism and HSC activation marker genes by NA808, a SPT inhibitor, were evaluated in an immortalized HSC cell line (E14C12). NA808 decreased sphingolipid synthesis and the expression of α-smooth muscle actin (α-SMA) and collagen 1A1 mRNA in HSC. We identified a novel oral SPT inhibitor, CH5169356, which is a prodrug of NA808. CH5169356 was administered in the Ath+HF model, a NASH mouse model with liver fibrosis induced by atherogenic and high-fat content diets. CH5169356 showed a significant decrease in the expression of α-SMA and collagen 1A1 mRNA in the liver and an inhibition of liver fibrosis progression. CH5169356 was also evaluated in a Stelic animal model (STAM), a NASH mouse model induced through a different mechanism than that of the Ath+HF model, and showed a significant anti-fibrotic effect. In conclusion, CH5169356 could inhibit the progression of hepatic fibrosis in the pathogenesis of NASH by suppressing HSC activation, suggesting that CH5169356 would be a potential oral NASH therapeutic agent.

An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis.

Non-alcoholic steatohepatitis (NASH) is a progressive fibrotic disease, the pathogenesis of which has not been fully elucidated. One of the most common models used in NASH research is a nutritional model where NASH is induced by feeding a diet deficient in both methionine and choline. However, the dietary methionine-/choline-deficient model in mice can cause severe weight loss and liver atrophy, which are not characteristics of NASH seen in human patients. Exclusive, long-term feeding with a high-fat diet (HFD) produced fatty liver and obesity in mice, but the HFD for several months did not affect fibrosis. We aimed to establish a mouse model of NASH with fibrosis by optimizing the methionine content in the HFD. Male mice were fed a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) consisting of 60 kcal% fat and 0.1% methionine by weight. After 1-14 weeks of being fed CDAHFD, the mice were killed. C57BL/6J mice maintained or gained weight when fed CDAHFD, while A/J mice showed a steady decline in body weight (of up to 20% of initial weight). In both strains of mice, plasma levels of alanine aminotransferase increased from week 1, when hepatic steatosis was also observed. By week 6, C57BL/6J mice had developed enlarged fatty liver with fibrosis as assessed by Masson's trichrome staining and by hydroxyproline assay. Therefore, this improved CDAHFD model may be a mouse model of rapidly progressive liver fibrosis and be potentially useful for better understanding human NASH disease and in the development of efficient therapies for this condition.

An orally available, small-molecule interferon inhibits viral replication.

Most acute hepatitis C virus (HCV) infections become chronic and some progress to liver cirrhosis or hepatocellular carcinoma. Standard therapy involves an interferon (IFN)-α-based regimen, and efficacy of therapy has been significantly improved by the development of protease inhibitors. However, several issues remain concerning the injectable form and the side effects of IFN. Here, we report an orally available, small-molecule type I IFN receptor agonist that directly transduces the IFN signal cascade and stimulates antiviral gene expression. Like type I IFN, the small-molecule compound induces IFN-stimulated gene (ISG) expression for antiviral activity in vitro and in vivo in mice, and the ISG induction mechanism is attributed to a direct interaction between the compound and IFN-α receptor 2, a key molecule of IFN-signaling on the cell surface. Our study highlights the importance of an orally active IFN-like agent, both as a therapy for antiviral infections and as a potential IFN substitute.

Genetic analysis of abdominal fat distribution in SM/J and A/J mice.

Each abdominal fat depot, such as mesenteric or epididymal, differently contributes to the development of insulin resistance. The aim of this study was to identify the genetic regions that contribute to fat accumulation in epididymal/mesenteric fat and to examine whether or not the genetic regions that affect glucose metabolism and body fat distribution are coincident. We previously mapped a major quantitative trait locus (QTL) (T2dm2sa) for impaired glucose tolerance on chromosome 2 and revealed that SM.A-T2dm2sa congenic mice showed not only glucose tolerance but also fat accumulation. In the present study, to identify the loci/genes that control the accumulation of abdominal fat, we performed QTL analyses of epididymal/mesenteric fat weight by using (A/J x SM.A-T2dm2sa)F2 mice in which the effect of T2dm2sa was excluded. As a result, two highly significant QTLs for mesenteric fat, as well as three significant QTLs for epididymal/mesenteric fat, were mapped on the different chromosomal regions. This suggests that the fat accumulations in individual fat depots are controlled by distinct genomic regions. Our comparison of these QTLs for abdominal fat distribution with those for glucose metabolism revealed that the major genetic factors affecting body fat distribution do not coincide with genetic factors affecting glucose metabolism in (A/J x SM.A-T2dm2sa)F2.

Confirmation of diabetes-related quantitative trait loci derived from SM/J and A/J mice by using congenic strains fed a high-carbohydrate or high-fat diet.

The interaction between causative genes and diet is known to influence the onset of obesity and diabetes in humans, although it has remained difficult to identify diabetogenic gene(s) because humans are genetically and environmentally heterogeneous. Mouse SMXA recombinant inbred (RI) strains are established from parental inbred strains (SM/J and A/J) and have been shown to be beneficial tools for analyzing polygenic traits. We previously mapped a significant quantitative trait locus (QTL, T2dm1sa) on Chromosome (Chr.) 10 and suggestive QTLs on Chr. 2, 6, and 18 for diabetes-related traits by using SMXA RI strains fed a high-carbohydrate diet. As a first step in identifying the responsible gene among QTLs for glucose tolerance mapped on Chr. 10 and 18, we established new strains of A.SM-T2dm1sa and SM.A-D18Mit19-D18Mit7 congenic mice. Each congenic strain bears the diabetogenic allele of an introgressed chromosomal region on a genetic background strain carrying the non-diabetogenic allele. The diabetogenic effect of T2dm1sa mapped on Chr. 10 was not supported by studies of A.SM-T2dm1sa congenic mice when the mice were fed a high-carbohydrate or high-fat diet. SM.A-D18Mit19-D18Mit7 congenic mice showed impaired glucose tolerance not only when they were fed a high-carbohydrate diet, but also when they were fed a high-fat diet. Thus, it appears that gene(s) affecting diabetes-related traits under either dietary condition may be present on Chr. 18.

Quantitative trait loci for impaired glucose tolerance in nondiabetic SM/J and A/J mice.

The SMXA-5 recombinant inbred strain, which was established from nondiabetic parental SM/J and A/J mice, develops diabetic phenotypes such as impaired glucose tolerance. The combination of diabetogenic genes in the SM/J and A/J genomes impairs glucose tolerance in SMXA-5 mice. Using (SM/J x SMXA-5)F2 mice fed a high-fat diet, we previously detected a diabetogenic locus, T2dm2sa, on chromosome (Chr) 2. The A/J allele at this locus is diabetogenic. The SM.A-T2dm2sa congenic mouse, in which the Chr 2 region of A/J including T2dm2sa was introgressed into SM/J, showed obviously impaired glucose tolerance. These results indicate that SM.A-T2dm2sa mice develop diabetogenic traits due to T2dm2sa with the A/J allele and unknown diabetogenic loci with the SM/J allele. The aim of this study was to dissect these unknown loci, using quantitative trait locus (QTL) analysis in the (A/J x SM.A-T2dm2sa) F2 intercross fed a high-fat diet. The results revealed a highly significant QTL, T2dm4sa, for glucose tolerance on Chr 6 and a significant QTL, T2dm5sa, for glucose tolerance on Chr 11. These loci with the SM/J allele were diabetogenic. The diabetogenic effect of T2dm4sa or T2dm5sa was verified by the impairment of glucose tolerance in the A/J-6(SM) or A/J-11(SM) consomic strain, in which Chr 6 or Chr 11 of SM/J is introgressed into A/J, respectively. These results demonstrate that diabetogenic loci exist in the genomes of nondiabetic A/J and SM/J mice and suggest that T2dm2sa with the A/J allele and T2dm4sa and/or T2dm5sa with the SM/J allele elicit impaired glucose tolerance in SM.A-T2dm2sa mice.